BIOA Quote, Financials, Valuation and Earnings

Electromed has a net margin of -890.97% compared to Bioage Labs's net margin of 12.06%. Bioage Labs's return on equity of -- beat Electromed's return on equity of 16.57%.

Bioage Labs has a consensus price target of $6.00, signalling upside risk potential of 36.99%. On the other hand Electromed has an analysts' consensus of $38.00 which suggests that it could grow by 88.87%. Given that Electromed has higher upside potential than Bioage Labs, analysts believe Electromed is more attractive than Bioage Labs.

Bioage Labs has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Electromed has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.159%.

Bioage Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bioage Labs pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Bioage Labs quarterly revenues are $1.5M, which are smaller than Electromed quarterly revenues of $15.7M. Bioage Labs's net income of -$12.9M is lower than Electromed's net income of $1.9M. Notably, Bioage Labs's price-to-earnings ratio is -- while Electromed's PE ratio is 25.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioage Labs is -- versus 2.94x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Integra Lifesciences Holdings has a net margin of -890.97% compared to Bioage Labs's net margin of -6.61%. Bioage Labs's return on equity of -- beat Integra Lifesciences Holdings's return on equity of -1.88%.

Bioage Labs has a consensus price target of $6.00, signalling upside risk potential of 36.99%. On the other hand Integra Lifesciences Holdings has an analysts' consensus of $16.13 which suggests that it could grow by 30.15%. Given that Bioage Labs has higher upside potential than Integra Lifesciences Holdings, analysts believe Bioage Labs is more attractive than Integra Lifesciences Holdings.

Bioage Labs has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Integra Lifesciences Holdings has a beta of 1.164, suggesting its more volatile than the S&P 500 by 16.396%.

Bioage Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integra Lifesciences Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bioage Labs pays -- of its earnings as a dividend. Integra Lifesciences Holdings pays out -- of its earnings as a dividend.

Bioage Labs quarterly revenues are $1.5M, which are smaller than Integra Lifesciences Holdings quarterly revenues of $382.7M. Bioage Labs's net income of -$12.9M is higher than Integra Lifesciences Holdings's net income of -$25.3M. Notably, Bioage Labs's price-to-earnings ratio is -- while Integra Lifesciences Holdings's PE ratio is 70.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioage Labs is -- versus 0.59x for Integra Lifesciences Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Treace Medical Concepts has a net margin of -890.97% compared to Bioage Labs's net margin of -30.29%. Bioage Labs's return on equity of -- beat Treace Medical Concepts's return on equity of -47.17%.

Bioage Labs has a consensus price target of $6.00, signalling upside risk potential of 36.99%. On the other hand Treace Medical Concepts has an analysts' consensus of $9.73 which suggests that it could grow by 71.58%. Given that Treace Medical Concepts has higher upside potential than Bioage Labs, analysts believe Treace Medical Concepts is more attractive than Bioage Labs.

Bioage Labs has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Treace Medical Concepts has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Bioage Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Treace Medical Concepts offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bioage Labs pays -- of its earnings as a dividend. Treace Medical Concepts pays out -- of its earnings as a dividend.

Bioage Labs quarterly revenues are $1.5M, which are smaller than Treace Medical Concepts quarterly revenues of $52.6M. Bioage Labs's net income of -$12.9M is higher than Treace Medical Concepts's net income of -$15.9M. Notably, Bioage Labs's price-to-earnings ratio is -- while Treace Medical Concepts's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioage Labs is -- versus 1.68x for Treace Medical Concepts. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -890.97% compared to Bioage Labs's net margin of 0.18%. Bioage Labs's return on equity of -- beat Xtant Medical Holdings's return on equity of -26.62%.

Bioage Labs has a consensus price target of $6.00, signalling upside risk potential of 36.99%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 181.13%. Given that Xtant Medical Holdings has higher upside potential than Bioage Labs, analysts believe Xtant Medical Holdings is more attractive than Bioage Labs.

Bioage Labs has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.181, suggesting its less volatile than the S&P 500 by 118.091%.

Bioage Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bioage Labs pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Bioage Labs quarterly revenues are $1.5M, which are smaller than Xtant Medical Holdings quarterly revenues of $32.9M. Bioage Labs's net income of -$12.9M is lower than Xtant Medical Holdings's net income of $58K. Notably, Bioage Labs's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioage Labs is -- versus 0.70x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.